Key Performance
More- Earnings Score: N/A
- Momentum Score: 23
- True Yield: N/A
- Financial Health Score: N/A
%20scale(1,1)}%2025%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(1,1)}}%20%23ewMkZ6d8Hun3_ts%20{animation:%20ewMkZ6d8Hun3_ts__ts%204000ms%20linear%20infinite%20normal%20forwards}@keyframes%20ewMkZ6d8Hun3_ts__ts%20{%200%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}%2025%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}}%20]]%3e%3c/style%3e%3cdefs%3e%3clinearGradient%20id='ewMkZ6d8Hun2-fill'%20x1='12.5'%20y1='23.5001'%20x2='-0.868518'%20y2='16.4047'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun2-fill-0'%20offset='0%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun2-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3clinearGradient%20id='ewMkZ6d8Hun3-fill'%20x1='31.5059'%20y1='27.1026'%20x2='10.2884'%20y2='14.9373'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun3-fill-0'%20offset='4.7%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun3-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3c/defs%3e%3cg%20id='ewMkZ6d8Hun2_ts'%20transform='translate(24.943161,19.954806)%20scale(1,1)'%3e%3cpath%20d='M14.8466,29.2814c0,0-14.408088-4.6983-12.05895-19.79995c0,0,1.50345,4.85085,4.13448,5.30845s-2.03592,4.6373,7.92447,14.4915Z'%20transform='translate(-24.943161,-19.954806)'%20fill='url(%23ewMkZ6d8Hun2-fill)'/%3e%3c/g%3e%3cg%20id='ewMkZ6d8Hun3_ts'%20transform='translate(24.9787,20.012362)%20scale(1,1)'%3e%3cpath%20d='M37.4922,21.9282l4.0719.244v-12.81353C31.0713,3.28748,17.7595,7.6502,17.7595,7.6502c.3445-4.51526-3.5707-5.52204-3.5707-5.52204c2.5371,1.52542.3132,6.22373.3132,6.22373C13.0299,0.084092,0,1.02986,0,1.02986C8.92672,4.35528,6.70287,7.98579,6.8908,16.6197c.18794,8.6034,8.3943,12.9966,8.3943,12.9966l-6.60895-.2441v13.2407c0,0,5.48135,2.3797,13.68765,3.1729v-22.3017h-4.4477c-1.0023,0-1.942-.8237-1.942-1.8v-5.7356c0-.9763.9397-1.8,1.942-1.8h4.4477v-1.3424h5.0115v1.3424h5.0115c1.0023,0,1.848.7932,1.848,1.8v5.7356c0,.9763-.8144,1.8-1.848,1.8h-5.0115v22.5153h.2819c11.1192-.0611,15.9428-7.3221,16.256-13.3017.4698-7.7492-6.421-10.7695-6.421-10.7695Z'%20transform='translate(-24.9787,-20.012361)'%20fill='url(%23ewMkZ6d8Hun3-fill)'/%3e%3c/g%3e%3c/svg%3e)
Latest Research & News
Kailera Therapeutics Debut Marks Largest Biotech IPO Since 2021 Amid Weight Loss Race
Kailera Therapeutics completed the largest biotech IPO since 2021, raising $625 million at $16 per share. The company is developing GLP-1-based obesity treatments, with its lead candidate ribupatide in Phase 3 trials. Kailera enters a competitive $200 billion obesity market dominated by Eli Lilly and Novo Nordisk, with promising early data showing up to 12.1% weight loss in oral formulation trials.
04/17/2026, 1:23 PM • Benzinga
U.S. stock futures rose on Tuesday following Monday's rally, with major indices trading higher. Vice President JD Vance signaled potential progress in Iran nuclear talks if Tehran meets U.S. demands. Investors await March producer price index data. Key movers include Sana Biotechnology surging 20% on Mayo Clinic collaboration, ChargePoint jumping 6.63% on insider buying, and Chevron declining despite a Venezuela oil production agreement. Professor Jeremy Siegel warns of near-term market caution due to rising oil prices and money growth concerns.
04/14/2026, 5:12 AM • Benzinga
Sana Biotechnology published research in Nature Biotechnology demonstrating successful in vivo gene editing of human hematopoietic stem cells using fusogen technology, potentially transforming treatment for diseases like sickle cell and beta thalassemia without conditioning chemotherapy.
12/08/2025, 9:00 AM • GlobeNewswire
Sana Biotech Stock — The Next '100-Bagger'?
Stock promoter Eric Jackson highlighted Sana Biotechnology as a potential '100-bagger' stock, citing falling interest rates, cooling inflation, and biotech sector revival as key catalysts.
10/15/2025, 12:15 PM • Benzinga
Quell Therapeutics Establishes World-Class Scientific Advisory Board
Quell Therapeutics has formed a Scientific Advisory Board comprising leading experts in immunology, T-regulatory cell biology, and autoimmune diseases to guide its innovative CAR-Treg cell therapy development.
08/27/2025, 7:00 AM • GlobeNewswire
Sana Biotechnology Announces Pricing of Public Offering
Sana Biotechnology has priced a public offering of 20,895,522 shares at $3.35 per share and pre-funded warrants, expecting to raise approximately $75 million. Morgan Stanley, Goldman Sachs, BofA Securities, and TD Cowen are joint book-running managers for the offering.
08/06/2025, 11:24 PM • Benzinga
Sana Biotechnology Announces Pricing of Public Offering
Sana Biotechnology plans to raise approximately $75 million through a public offering of 20,895,522 common shares and pre-funded warrants at $3.35 per share, with Morgan Stanley, Goldman Sachs, BofA Securities, and TD Cowen as joint book-running managers.
08/06/2025, 11:24 PM • GlobeNewswire
Draig Therapeutics, a clinical-stage neuropsychiatric drug development company, appointed Douglas E. Williams, Ph.D. as independent Chair of its Board of Directors. Dr. Williams brings over 30 years of biotech leadership experience from companies like Biogen and Amgen.
07/15/2025, 4:00 AM • GlobeNewswire
Peers
Statistics
MoreInformation as of 06/22/2026
Company Profile
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology. The company's product pipeline includes UP421, a HIP-modified allogeneic primary islet cell product, which is in phase 1 clinical trial to treat type 1 diabetes; SC451, a HIP-modified, stem cell derived pancreatic islet cell therapy, which is in preclinical trial for the treatment of type 1 diabetes; SG293 and SG299, a CD8-targeted fusosome for the treatment of B cell hematologic malignancies and B cell mediated autoimmune diseases. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company has a strategic collaboration with Mayo Clinic for the development of SC451, a hypoimmune-modified pancreatic islet cell therapy for type 1 diabetes. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.